Alkermes Plc (ALKS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Alkermes Plc (ALKS) has a cash flow conversion efficiency ratio of 0.093x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($170.07 Million) by net assets ($1.82 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Alkermes Plc - Cash Flow Conversion Efficiency Trend (1991–2025)
This chart illustrates how Alkermes Plc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read ALKS total liabilities for a breakdown of total debt and financial obligations.
Alkermes Plc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Alkermes Plc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Budimex S.A.
WAR:BDX
|
-0.066x |
|
CCOOP Group Co Ltd
SHE:000564
|
-0.007x |
|
Wacker Chemie AG
XETRA:WCH
|
0.110x |
|
Dianthus Therapeutics Inc.
NASDAQ:DNTH
|
-0.095x |
|
Merdeka Copper Gold PT
JK:MDKA
|
0.019x |
|
Loncin Motor Co Ltd
SHG:603766
|
0.084x |
|
SCOR.ADR1/10/EO-78769723
F:SDRB
|
N/A |
|
AGL Energy Ltd
AU:AGL
|
0.115x |
Annual Cash Flow Conversion Efficiency for Alkermes Plc (1991–2025)
The table below shows the annual cash flow conversion efficiency of Alkermes Plc from 1991 to 2025. For the full company profile with market capitalisation and key ratios, see Alkermes Plc (ALKS) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $1.82 Billion | $520.75 Million | 0.286x | -4.51% |
| 2024-12-31 | $1.46 Billion | $439.12 Million | 0.300x | -10.18% |
| 2023-12-31 | $1.20 Billion | $401.35 Million | 0.334x | +1555.17% |
| 2022-12-31 | $1.04 Billion | $21.04 Million | 0.020x | -77.95% |
| 2021-12-31 | $1.11 Billion | $101.72 Million | 0.091x | +17.75% |
| 2020-12-31 | $1.07 Billion | $82.84 Million | 0.078x | +16.92% |
| 2019-12-31 | $1.09 Billion | $72.08 Million | 0.066x | -21.66% |
| 2018-12-31 | $1.17 Billion | $99.28 Million | 0.085x | +431.28% |
| 2017-12-31 | $1.20 Billion | $19.19 Million | 0.016x | +130.24% |
| 2016-12-31 | $1.21 Billion | $-63.80 Million | -0.053x | -71.78% |
| 2015-12-31 | $1.31 Billion | $-40.36 Million | -0.031x | -485.09% |
| 2014-12-31 | $1.40 Billion | $11.14 Million | 0.008x | -90.79% |
| 2013-12-31 | $1.07 Billion | $92.20 Million | 0.087x | -34.86% |
| 2012-12-31 | $952.37 Million | $126.55 Million | 0.133x | +4671.29% |
| 2011-12-31 | $853.85 Million | $-2.48 Million | -0.003x | +80.71% |
| 2010-12-31 | $392.02 Million | $-5.91 Million | -0.015x | +49.24% |
| 2009-12-31 | $412.62 Million | $-12.25 Million | -0.030x | -135.97% |
| 2008-12-31 | $419.23 Million | $34.59 Million | 0.083x | -40.62% |
| 2007-12-31 | $305.31 Million | $42.42 Million | 0.139x | -36.16% |
| 2006-12-31 | $384.65 Million | $83.73 Million | 0.218x | -64.09% |
| 2005-12-31 | $192.24 Million | $116.53 Million | 0.606x | +103.36% |
| 2004-12-31 | $4.11 Million | $-74.25 Million | -18.058x | -246.28% |
| 2003-12-31 | $18.84 Million | $-98.25 Million | -5.215x | -957.19% |
| 2002-12-31 | $98.82 Million | $-48.75 Million | -0.493x | +32.56% |
| 2001-12-31 | $58.35 Million | $-42.68 Million | -0.731x | -392.56% |
| 2000-12-31 | $121.14 Million | $-17.99 Million | -0.148x | +27.45% |
| 1999-12-31 | $161.37 Million | $-33.03 Million | -0.205x | -133.92% |
| 1998-12-31 | $162.85 Million | $-14.25 Million | -0.088x | -1183.18% |
| 1997-12-31 | $166.69 Million | $-1.14 Million | -0.007x | +96.86% |
| 1996-12-31 | $79.15 Million | $-17.18 Million | -0.217x | -32.13% |
| 1995-12-31 | $33.49 Million | $-5.50 Million | -0.164x | +61.74% |
| 1994-12-31 | $21.20 Million | $-9.10 Million | -0.429x | -11.32% |
| 1993-12-31 | $31.90 Million | $-12.30 Million | -0.386x | -206.54% |
| 1992-12-31 | $47.70 Million | $-6.00 Million | -0.126x | +84.92% |
| 1991-12-31 | $54.20 Million | $-45.20 Million | -0.834x | -- |
About Alkermes Plc
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and … Read more